AcuCort Past Earnings Performance
Past criteria checks 0/6
AcuCort's earnings have been declining at an average annual rate of -16.6%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 28.9% per year.
Key information
-16.6%
Earnings growth rate
1.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | 28.9% |
| Return on equity | -32.5% |
| Net Margin | -203.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How AcuCort makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 7 | -14 | 20 | 0 |
| 31 Dec 23 | 7 | -14 | 20 | 0 |
| 30 Sep 23 | 6 | -13 | 3 | 0 |
| 30 Jun 23 | 5 | -14 | 5 | 0 |
| 31 Mar 23 | 5 | -15 | 4 | 0 |
| 31 Dec 22 | 5 | -15 | 4 | 0 |
| 30 Sep 22 | 5 | -14 | 14 | 0 |
| 30 Jun 22 | 5 | -13 | 3 | 0 |
| 31 Mar 22 | 4 | -13 | 3 | 0 |
| 31 Dec 21 | 3 | -11 | 3 | 0 |
| 30 Sep 21 | 1 | -10 | 3 | 0 |
| 30 Jun 21 | 1 | -9 | 3 | 0 |
| 31 Mar 21 | 1 | -8 | 2 | 0 |
| 31 Dec 20 | 2 | -8 | 2 | 0 |
| 30 Sep 20 | 6 | -8 | -2 | 0 |
| 30 Jun 20 | 5 | -9 | 0 | 0 |
| 31 Mar 20 | 5 | -9 | 2 | 0 |
| 31 Dec 19 | 4 | -8 | 3 | 0 |
| 30 Sep 19 | 0 | -8 | 8 | 0 |
| 30 Jun 19 | 0 | -6 | 6 | 0 |
| 31 Mar 19 | 0 | -6 | 6 | 0 |
| 31 Dec 18 | 0 | -6 | 6 | 0 |
| 30 Sep 18 | 0 | -5 | 5 | 0 |
| 30 Jun 18 | 0 | -5 | 5 | 0 |
| 31 Mar 18 | 0 | -5 | 5 | 0 |
| 31 Dec 17 | 0 | -5 | 5 | 0 |
| 30 Sep 17 | 0 | -5 | 5 | 0 |
| 30 Jun 17 | 0 | -4 | 4 | 0 |
| 31 Mar 17 | 0 | -3 | 3 | 0 |
| 31 Dec 16 | 0 | -2 | 2 | 0 |
| 31 Dec 15 | 0 | -2 | 2 | 0 |
| 31 Dec 14 | 0 | -3 | 3 | 0 |
Quality Earnings: ACUC is currently unprofitable.
Growing Profit Margin: ACUC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACUC is unprofitable, and losses have increased over the past 5 years at a rate of 16.6% per year.
Accelerating Growth: Unable to compare ACUC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACUC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.5%).
Return on Equity
High ROE: ACUC has a negative Return on Equity (-32.49%), as it is currently unprofitable.